Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
MWN-AI** Summary
Cryo-Cell International, Inc. (NYSE American LLC: CCEL), a pioneer in private cord blood banking, reported its financial results for the fiscal year ending November 30, 2025, revealing a modest decline in revenue. Consolidated revenues reached $31.6 million, down slightly from $32.0 million in 2024. The bulk of this revenue, $31.4 million, came from processing and storage fees, while product revenue was $54,000 and public banking revenue contributed $130,000. In comparison, the previous year saw $31.6 million in processing and storage fees, $68,000 in product revenue, and $367,000 in public banking revenue.
The Company also faced a significant net loss of $2.4 million in 2025, equating to $0.30 per basic and diluted share, a shift from a net income of $402,000, or $0.05 per share, in 2024. This financial downturn was largely attributed to a $4.4 million impairment charge recorded during the fourth quarter, reflecting a reassessment of the expected recoverability of capitalized inventory, particularly in public banking.
Founded in 1989, Cryo-Cell has positioned itself at the forefront of stem cell storage, processing over 500,000 cord blood samples globally and partnering with Duke University in public banking. Their FDA-registered facility boasts stringent compliance and high-quality standards, having received numerous accreditations.
Despite the financial challenges, Cryo-Cell remains focused on expanding its core services and exploring new biopharmaceutical opportunities, aiming to enhance its clinical offerings and overall market position. The company has communicated that forward-looking statements in its report reflect current expectations and involve inherent risks and uncertainties, further suggesting caution in interpreting potential future performance.
MWN-AI** Analysis
Cryo-Cell International, Inc. (NYSE American: CCEL) has reported a challenging fiscal year ending November 30, 2025, facing a dip in revenues and a significant net loss compared to the previous year. The company generated consolidated revenues of $31.6 million, a slight decrease from $32.0 million in fiscal 2024, driven primarily by a decrease in processing and storage fee revenue. The notable rise in net loss to $2.4 million, accompanied by a $4.4 million impairment charge, underscores the potential challenges Cryo-Cell faces in maintaining profitability and managing inventory effectively.
Investors should approach Cryo-Cell with caution. The company’s operational challenges, evidenced by declining revenues and increasing losses, may signal underlying issues within its business model. The dip in public banking revenue and a considerable impairment charge raise questions about market demand and inventory management practices. However, it is worthwhile to note Cryo-Cell’s established reputation as the world’s first private cord blood bank and its extensive experience in the field. The company maintains compliance with FDA regulations and holds multiple accreditations, enhancing its credibility.
Looking forward, the potential risks outlined in Cryo-Cell's forward-looking statements should be carefully considered. Key uncertainties include the success of global expansion initiatives, competitive pressures from public banks, and the viability of new product lines. These factors could hinder revenue growth and profitability.
For investors considering an entry into Cryo-Cell, a strategy that includes monitoring operational changes and developments in product offerings is crucial. With new initiatives like ExtraVault services and the potential spinoff of Celle Corp, a cautious and informed approach may lead to future opportunities, but the current landscape requires vigilance given the company’s financial performance in 2025.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025.
Financial Results
Revenue
Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024.
Net (Loss) Income
The Company reported a net loss of $2.4 million in fiscal 2025 or $0.30 per basic and diluted share, compared to net income of $402,000 in fiscal 2024 or $0.05 per basic and diluted share. Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $4.4 million was recognized during the fourth quarter of November 30, 2025 to reduce the public inventory from cost to net realizable value.
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. ?More than 500,000 parents from 87 countries have entrusted Cryo-Cell International, Inc. with ?their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell ?International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell’s ?public bank has provided cord blood for more than 700 transplants and operates a cord ?blood donation site at one of the country’s most prominent hospitals, Cedars–Sinai Hospital in ?Los Angeles. Cryo-Cell’s facility is FDA registered, cGMP-/cGTP-?compliant and licensed in all states requiring licensure. Besides being AABB accredited as a ?cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to ?receive FACT accreditation for adhering to the most stringent cord blood quality standards ?set by any internationally recognized, independent accrediting organization. Cryo-Cell has ?the exclusive rights ?to PrepaCyte-CB, the industry’s most advanced cord blood processing ?technology.?
Cryo-Cell’s mission is to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terminology such as “will,” “may,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company’s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company’s Form 10-Q filed on October 15, 2025.
This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260227119036/en/
Irene Smith
813-749-2102
Ismith@cryo-cell.com
FAQ**
How does Cryo-Cell International, Inc. CCEL plan to address the decline in revenue from $32.0 million in fiscal 2024 to $31.6 million in fiscal 2025, particularly in processing and storage fee revenue?
Given the net loss of $2.4 million in fiscal 2025, what strategies is Cryo-Cell International, Inc. CCEL implementing to return to profitability in the coming fiscal years?
How does the $4.4 million impairment charge affect Cryo-Cell International, Inc. CCEL's inventory management and future financial projections?
What role do Cryo-Cell International, Inc. CCEL's collaborative research partnerships play in its long-term growth plans, and how might they influence revenue streams and product diversification?
**MWN-AI FAQ is based on asking OpenAI questions about Cryo-Cell International, Inc. (NYSE: CCEL).
NASDAQ: CCEL
CCEL Trading
0.0% G/L:
$3.18 Last:
308 Volume:
$3.18 Open:
